These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy. Morales E; Andrés A; González E; Herrero JC; Muñoz MA; Ortiz M; Espejo B; Lumbreras C; Morales JM; Aguado JM Transplant Proc; 2002 Feb; 34(1):73-4. PubMed ID: 11959191 [No Abstract] [Full Text] [Related]
27. Editorial commentary: Use of valganciclovir for prevention and treatment of cytomegalovirus disease. Snydman DR Clin Infect Dis; 2008 Jan; 46(1):28-9. PubMed ID: 18171209 [No Abstract] [Full Text] [Related]
28. Ganciclovir prophylaxis for CMV disease infrequently associated with viral resistance. AIDS Patient Care; 1995 Dec; 9(6):308. PubMed ID: 11361450 [No Abstract] [Full Text] [Related]
34. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523 [TBL] [Abstract][Full Text] [Related]
35. Superior efficacy of oral ganciclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients. Somerville T; Hurst G; Alloway R; Gaber A; Shokouh-Amiri MH; Stratta R Transplant Proc; 1998 Jun; 30(4):1546-8. PubMed ID: 9636628 [No Abstract] [Full Text] [Related]
36. Emergence of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Bienvenu B; Thervet E; Bedrossian J; Scieux C; Mazeron MC; Thouvenot D; Legendre C Transplant Proc; 2000 Mar; 32(2):407. PubMed ID: 10715457 [No Abstract] [Full Text] [Related]
37. Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation). Chong PP; Teiber D; Prokesch BC; Arasaratnam RJ; Peltz M; Drazner MH; Garg S Transpl Infect Dis; 2018 Oct; 20(5):e12965. PubMed ID: 29989279 [TBL] [Abstract][Full Text] [Related]
38. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Gilbert C; Roy J; Belanger R; Delage R; Beliveau C; Demers C; Boivin G Antimicrob Agents Chemother; 2001 Dec; 45(12):3669-71. PubMed ID: 11709367 [TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden. Johanssson I; Mårtensson G; Andersson R Scand J Infect Dis; 2010; 42(2):129-36. PubMed ID: 20082575 [TBL] [Abstract][Full Text] [Related]
40. Prophylaxis of human cytomegalovirus infection in renal transplant patients with valacyclovir and ganciclovir. Zhang P; Wang W; Zhang L; Li SF; Guan LB; Dong LQ; Zhou S; Yu P Acta Virol; 2013; 57(3):375-7. PubMed ID: 24020766 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]